The Broker Innovation Lab celebrates brokers and other benefits stakeholders who have embraced the changing marketplace to position themselves and their business for future success
Patients who have experienced severe stomach complications from the new class of GLP-1 weight loss drugs are now suing Novo Nordisk and Eli Lilly alleging that the drugmakers misled doctors on the drugs' potential risks.